Latest news with #AHH
Time of India
a day ago
- Business
- Time of India
Asia Healthcare Holdings to invest Rs 400 crore in Asian Institute of Nephrology and Urology to double hospital network
Asia Healthcare Holdings , a leading healthcare investment platform backed by Singapore's GIC and TPG, will invest Rs 400 crore in Asian Institute of Nephrology and Urology (AINU), one of the largest single-speciality chains focused on uro-nephro care, in the next 4-5 years, AHH's executive chairman Vishal Bali told ET. AHH, which has currently over 70% stake in AINU, will invest this fund for growth and expansion of the urology and nephrology chain with plans to open 13 hospitals from current seven in the next 3-4 years – with most planned in Tier 2 towns such as Patna, Bhubaneshwar, Coimbatore, and others. Finance Value and Valuation Masterclass Batch-1 By CA Himanshu Jain View Program Finance Value and Valuation Masterclass - Batch 2 By CA Himanshu Jain View Program Finance Value and Valuation Masterclass - Batch 3 By CA Himanshu Jain View Program Artificial Intelligence AI For Business Professionals By Vaibhav Sisinity View Program Finance Value and Valuation Masterclass - Batch 4 By CA Himanshu Jain View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program The planned outlay of Rs 400 crore will take AHH's full investment in the chain to Rs 1,000 crore since FY24, making it one of the largest investments in the single-speciality format in the urology-nephrology space. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 'Rs 600 crore of our capital is in AINU and there is another Rs 400 crore outlay between now and FY30. That makes a total of Rs 1,000 crore investment that we will put behind this specialty,' said Bali. 'We will invest the fund in the growth creation of a much bigger footprint for AINU,' he added. 'We see a big opportunity at AHH in the creation and exponential growth of single specialty enterprises in the Tier 2 cities,' said Bali. Live Events Currently, AINU is present in seven locations including two Metro cities in Hyderabad and Chennai. All its other hospitals are in Tier 2 cities including places like Vizag and Siliguri. While its flagship centre in Hyderabad has 150 beds capacity, Chennai has 100 beds and the others in tier 2 are mostly 75 bedders. 'We are looking to ramp up the clinical capabilities and services in each of these hospitals. Robotic programme is an important service that we have – currently we have two centres offering this service – we want to start ramping it up in other centres,' said Sandeep Guduru, CEO, AINU. 'In our new centre in Banjara Hills in Hyderabad the focus is on setting up sub-specialities such as female neurology, paediatric neurology, etc. That's also a large part of our growth capex,' said Guduru. For FY 26-27, AHH has earmarked an outlay of Rs 150 crore capital expenditure in AINU to open 3-4 new urology and nephrology hospitals across India. India's market for single-specialty hospitals is set to more-than-double to $31 billion in three-four years from the current $15 billion. Most of it is private equity-led expansion into small towns and hinterlands where demand for quality healthcare services is growing rapidly, according to a report from investment bank Avendus. 'There are certain specialties that have come out of the multispecialty format and created a growth trajectory of their own,' said Bali. Explaining the fund's investment strategy, he said 'We are gung-ho about single specialty as it gives us the opportunity to scale quickly, our return on capital employed (ROCE) are much higher than what the multispecialty institutions see. From an India context this format will work very well because there is a replication opportunity.' The market share of single specialty hospitals, catering to segments like eyecare, oncology, fertility treatments and mother & child-care, urology and nephrology and dental care is expected to rise to 40% of the total healthcare market by 2028 from the current 30%, according to Avendus.
&w=3840&q=100)
Business Standard
a day ago
- Business
- Business Standard
GIC, TPG-backed AHH targets 20 AINU hospitals by FY30, eyes GI entry
Asian Healthcare Holdings (AHH), backed by Singapore sovereign wealth fund GIC and private equity firm TPG, plans to expand to about 20 nephrology and urology facilities under its Asian Institute of Nephrology and Urology (AINU) brand by the end of FY30. AINU currently operates over 500 beds in seven hospitals across Hyderabad, Visakhapatnam, Siliguri, and Chennai. It inaugurated a 200-bed flagship hospital in Hyderabad on Monday. 'Between FY26 and FY27, there will be another three to four hospitals, which will take our tally to 12-13 facilities,' Vishal Bali, executive chairman of AHH, told Business Standard. With this expansion, AINU's bed capacity will reach about 850. He added that the next phase of growth will focus on tier-II cities such as Bhubaneswar, Patna, Coimbatore, and Pune. Sandeep Guduru, chief executive officer of AINU, said Rs 150 crore in capital expenditure has been earmarked to open three to four new urology and nephrology facilities in the next 12 months. 'We are also expanding our robotic surgery capabilities in a couple of our other cities,' he added. Bali said that between FY27 and FY30, AINU could add another seven to eight hospitals, taking the total to around 20. AHH, which owns Motherhood Hospitals (maternity care), AINU, and Nova IVF (IVF), is a healthcare platform specialising in single-specialty hospitals. The network now plans to enter one or two additional specialties. 'Gastroenterology (GI) is one such specialty that we would be keen to explore,' Bali said. He explained that GI offers a strong outpatient department with endoscopy, as well as inpatient procedures largely driven by minimal access surgery. On the possibility of an initial public offering, Bali declined to share a timeline, saying it was a matter of when the investors deemed it appropriate. 'However, with the Ebitda that we have on the platform today, the company could potentially go to an IPO even in the next 16 or 18 months,' he said.
Yahoo
4 days ago
- Business
- Yahoo
Armada Hoffler Properties (AHH) Upgraded to Buy: What Does It Mean for the Stock?
Investors might want to bet on Armada Hoffler Properties (AHH), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time. Therefore, the Zacks rating upgrade for Armada Hoffler Properties basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price. Most Powerful Force Impacting Stock Prices The change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock. For Armada Hoffler Properties, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher. Harnessing the Power of Earnings Estimate Revisions As empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions. The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> . Earnings Estimate Revisions for Armada Hoffler Properties For the fiscal year ending December 2025, this real estate company is expected to earn $1.05 per share, which is unchanged compared with the year-ago reported number. Analysts have been steadily raising their estimates for Armada Hoffler Properties. Over the past three months, the Zacks Consensus Estimate for the company has increased 2.3%. Bottom Line Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term. You can learn more about the Zacks Rank here >>> The upgrade of Armada Hoffler Properties to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Armada Hoffler Properties, Inc. (AHH) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Time of India
24-06-2025
- Business
- Time of India
Asia Healthcare Holdings appoints Arvind N Sivaramakrishnan as Chief Technology Officer
Bengaluru: Asia Healthcare Holdings (India and South Asia) has appointed Arvind N Sivaramakrishnan as its Chief Technology Officer . According to AHH, the appointment aligns with its aim to strengthen technology-enabled and data-driven healthcare delivery across its portfolio. Sivaramakrishnan will lead the organisation's digital technology strategy , including infrastructure, cybersecurity, telehealth platforms , AI integration, and electronic health record (EHR) optimisation. Sivaramakrishnan has previously held leadership roles in both Indian and global healthcare organisations. He began his career at Ramco Systems and later worked at DXC Technology, where he oversaw the Clinical Applications Portfolio for Henry Ford Health Systems in the US. In 2011, he returned to India as Group CIO at Apollo Hospitals, where he led digital transformation efforts for over a decade. Most recently, he served as Chief Information Officer at Karkinos Healthcare. He also holds advisory roles, including Vice Chairman of the Board of Advisors for HIMSS Asia Pacific and a member of the Privacy Advisory Panel for healthcare services under the Data Security Council of India.
Mint
05-05-2025
- Business
- Mint
GIC-backed Asia Healthcare Holdings to acquire Dr Dangs Labs
MUMBAI : Asia Healthcare Holdings (AHH), backed by Singapore's sovereign wealth fund GIC, is set to acquire a majority stake in Dr Dangs Labs, a diagnostic chain operating in Delhi and Gurugram, according to two people aware of the development. This marks the fourth acquisition by AHH, following previous deals with Motherhood Hospitals, the Asian Institute of Nephrology and Urology (AINU), and Nova IVF. Details of the financial terms of the deal were not disclosed. Read this | Singles are hot: Why private equity firms are increasingly investing in these hospitals AHH's earlier investment in AINU in 2023, valued at ₹ 600 crore, involved both primary and secondary funding. AHH has also seen significant capital inflows, including a $150 million investment from GIC in December 2024, which made the sovereign fund the largest shareholder in the company. GIC had also invested $170 million in AHH in February 2022. Before GIC's additional investment, AHH was majority-owned by global private equity firm TPG, which now holds a minority stake in the platform. The GIC investment likely valued AHH at $800-900 million, Mint reported earlier. With plans to eventually go public, AHH is gearing up for an initial public offering (IPO), although no timeline has been provided. According to Vishal Bali, executive chairman of AHH, profitability is not a concern as the company moves towards its listing, which is expected within the next few years. Dr Dangs Labs operates seven centres across Delhi and Gurugram and reported a revenue of ₹ 67.7 crore for the financial year ended 31 March 2024, according to Tracxn. Read this | Jashvik Capital to acquire over 50% stake in Smart Vision Eye Hospitals Bali has reportedly said that AHH is growing at 25% year-on-year and aims to reach nearly ₹ 6,000 crore in revenue by FY32. AHH declined to comment on the acquisition, and Dr Dangs Labs did not respond to an email request for information at the time of publication. India's healthcare and diagnostics sector has seen a sharp uptick in private equity investments and mergers and acquisitions (M&A) in recent years. According to a report by Grant Thornton Bharat and the Association of Healthcare Providers of India (AHPI), India's healthcare and pharma sector recorded 594 transactions valued at over $30 billion between 2022 and 2024. Foreign direct investment (FDI) in the sector also rose, totalling $3.2 billion during the same period. Also read | India's fragmented hospital sector ripe for consolidation: Rothchild's Hollamby In recent months, there have been notable deals within the diagnostics space. Neuberg Diagnostics raised ₹ 9,400 million from Kotak Alt in January 2025, marking the largest primary fund-raise in Indian diagnostics and the company's first private equity round. Meanwhile, Temasek Holdings and Oswal Alternates jointly invested approximately $85 million in Molbio Diagnostics in 2024, and Fortis Healthcare increased its stake in Agilus Diagnostics from 57% to 91% by acquiring a 34% stake from private equity firms Jacob Ballas and IFC.
